UNSPSC 51343509: Tenofovir alafenamide fumarate

This classification denotes a reverse transcriptase inhibitor and purine antagonist 2C21H29N6O5P.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FWF6Q91TZO, chemically known as l-alanine, n-((s)-(((1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy)methyl)phenoxyphosphinyl)-, 1-methylethyl ester, (2e)-2-butenedioate (2:1), but more generally known as tenofovir alafenamide fumarate, which bears US NIH Compound Identifier 71301443.

Most nations, for tariff and trade purposes, schedule tenofovir alafenamide fumarate under HS 29335995 and SITC 51576. As of Q4 2014, TENOFOVIR ALAFENAMIDE FUMARATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@H](CN1CNC2C1NCNC2N)OC[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3CCCCC3.C[C@H](CN1CNC2C1NCNC2N)OC[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3CCCCC3.C(=C/C(=O)O)\C(=O)O.

UNSPSC 51343509 Tenofovir alafenamide fumarate, a Commodity code, shows limited recent state and local procurement activity aligned with its nominal pharmaceutical scope. The recent opportunities tagged under this code span medical and first aid supplies, naloxone procurement, generic pharmaceuticals through cooperative purchasing, and direct-to-manufacturer pharmacy benefit programs — suggesting either misalignment between the code's specificity and how jurisdictions tag acquisitions, or very narrow demand for this particular antiretroviral formulation in state and local markets. The work actually being solicited includes emergency-response medical consumables, opioid-reversal products, and broad generic pharmaceutical supply arrangements rather than targeted acquisitions of tenofovir alafenamide fumarate itself.

Issuing bodies include a Florida county health authority (Seminole County), a Texas state health commission, a municipal fire department (City of Tampa), and a multi-state cooperative purchasing alliance (MMCAP). The most concrete and recent opportunity is the City of Tampa's IFB for medical and first aid supplies for the Fire Department Rescue Division, due March 13, 2026, with an estimated contract value of $700,000 and a 5 percent small local business enterprise bid discount available; Seminole County's IFB for naloxone and drug deactivation systems, due July 26, 2023, with quarterly deliveries; and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, due March 26, 2026, with contract awards effective July 1, 2026. The Texas HHS Commission's April 2026 Request for Information on direct-to-manufacturer prescription programs represents exploratory market intelligence rather than a binding procurement. Geographic activity appears concentrated in Florida (Seminole County, Tampa), Texas (state HHS), and the MMCAP footprint (Minnesota and Oregon), with no clear signal of widespread adoption of this code for antiviral pharmaceutical procurement at state and local level.